Macquarie Group Ltd. grew its stake in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 7.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,402 shares of the biopharmaceutical company’s stock after buying an additional 5,002 shares during the quarter. Macquarie Group Ltd. owned approximately 0.16% of Sucampo Pharmaceuticals worth $854,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. HPM Partners LLC purchased a new stake in Sucampo Pharmaceuticals in the second quarter worth about $1,307,000. Louisiana State Employees Retirement System increased its position in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 100 shares in the last quarter. Nine Chapters Capital Management LLC purchased a new stake in Sucampo Pharmaceuticals in the third quarter worth about $127,000. JPMorgan Chase & Co. purchased a new stake in Sucampo Pharmaceuticals in the second quarter worth about $117,000. Finally, Aperio Group LLC purchased a new stake in Sucampo Pharmaceuticals in the third quarter worth about $137,000. Institutional investors and hedge funds own 65.31% of the company’s stock.
Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at $16.00 on Monday. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. Sucampo Pharmaceuticals, Inc. has a 1 year low of $9.30 and a 1 year high of $17.70. The stock has a market capitalization of $746.19, a PE ratio of 10.96, a P/E/G ratio of 4.76 and a beta of 1.47.
SCMP has been the subject of a number of analyst reports. initiated coverage on Sucampo Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $14.00 price target for the company. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. UBS reduced their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, October 12th. Mizuho reiterated a “hold” rating and set a $12.00 target price on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 1st. Finally, Maxim Group reiterated a “buy” rating and set a $23.00 target price on shares of Sucampo Pharmaceuticals in a research report on Thursday, November 2nd. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $16.60.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.